NCT02074865

Brief Summary

The main challenge of the ChARLI program is to assess the clinical burden of severe neonatal and childhood bacterial infections in low-income countries,in particular those caused by antibiotic resistant bacteria. This program will address both healthcare associated, as well as community acquired infections. Beside its main challenge, the ChARLI program will also allow the assessment of the economic burden of these infections, the improvement of their medical care and then ultimately help to set public health interventions and guide public health measures necessary to combat bacterial infections and bacterial resistance in children. It will also lead to set up more basic research investigation to better understand how pathogenic and epidemic may be the resistant clones in these countries and to experiment innovative strategies devoted to prevent these infections. In order to achieve these objectives, an international paediatric cohort will be created, and monitored a platform. This will be done first within the Institut Pasteur International Network (IPIN) and possibly extended in some others low income countries where the IPIN has no center. This constituted initiative will represent the first international pediatric program of its size to be located in low-income countries and specifically focusing severe bacterial infections and bacterial resistance to antibiotics

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2012

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

July 10, 2013

Completed
8 months until next milestone

First Posted

Study publicly available on registry

February 28, 2014

Completed
1 day until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2014

Completed
Last Updated

February 28, 2014

Status Verified

February 1, 2014

Enrollment Period

1.5 years

First QC Date

July 10, 2013

Last Update Submit

February 25, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • Incidence of infections with bacteria resistant to antibiotics in neonates and young children (up to 18 months of age).

    27 months

Secondary Outcomes (2)

  • Bacterial aetiology of neonatal infection in low income countries and its resistance

    27 months

  • Identification of factors responsible of the dissemination and transmission of multiresistant resistant bacteria in low incomes countries

    27 months

Study Arms (1)

newborns

Biological: biological samples

Interventions

newborns

Eligibility Criteria

Age1 Minute - 3 Days
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)
Sampling MethodProbability Sample
Study Population

newborns

You may qualify if:

  • Neonate born to parents living in the study zone of a participating country
  • Parents of the neonate not intending to move away from the study zone during the follow-up period
  • Legal guardians of the neonate informed about the way in which the study is to be carried out and about the collection of biological samples
  • Legal guardians of the neonate having no objection to the collection of biological samples
  • Authorisation from at least one of the legal guardians of the child, in the form of a signed informed consent form.

You may not qualify if:

  • Stillborn neonate
  • Parents of the neonate living outside the study zone of a participating country
  • Neonate born to parents planning to move away from the study zone of a participating country during the follow-up period
  • At least one of the legal guardians of the neonate not informed about the study or about the collection of biological samples
  • At least one of the legal guardians of the neonate opposed to the collection of biological samples.
  • Neonate already participating in another biomedical study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

institut pasteur in Madagascar

Antananarivo, Madagascar

RECRUITING

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

At birth, for therapeutic management of the newborns in the presence of a risk factor for infection :gastric fluid, external auditory canal swabs, anal swabs, placental biopsy. Before empirical antibiotic treatment: blood cultures, blood sampling for CRP determination.In the presence of particular warning signs of infection chest X ray and lumbar puncture. During the follow-up, for therapeutic management of the newborns if the child has a suspected infection : urine samples, blood for blood cultures and Blood formula and C-reactive protein (CRP) detrmination; rhinopharyngeal fluid samples, lumbar puncture in febrile children under the age of three months; and thick blood smears if the child has a fever. Samples based on the presence of particular warning signs of infection: stool samples, eye or ear swabbing, chest X

MeSH Terms

Conditions

Bacterial Infections

Condition Hierarchy (Ancestors)

Bacterial Infections and MycosesInfections

Central Study Contacts

Didier Guillemot, MD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 10, 2013

First Posted

February 28, 2014

Study Start

September 1, 2012

Primary Completion

March 1, 2014

Last Updated

February 28, 2014

Record last verified: 2014-02

Locations